# Silymarin (Milk Thistle Extract) in Treating Patients With Acute Lymphoblastic Leukemia Who Are Receiving Chemotherapy

> **NCT00055718** · PHASE2 · COMPLETED · sponsor: **Herbert Irving Comprehensive Cancer Center** · enrollment: 50 (estimated)

## Conditions studied

- Drug/Agent Toxicity by Tissue/Organ
- Leukemia

## Interventions

- **DIETARY_SUPPLEMENT:** silymarin

## Key facts

- **NCT ID:** NCT00055718
- **Lead sponsor:** Herbert Irving Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-11
- **Primary completion:** —
- **Final completion:** 2010-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2013-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00055718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00055718, "Silymarin (Milk Thistle Extract) in Treating Patients With Acute Lymphoblastic Leukemia Who Are Receiving Chemotherapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00055718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*